MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2025 International Congress

    Improved Decision-Making for In-Hospital Medication Management in Parkinson’s Disease

    R. Diaz-Rincon, M. Liang, A. Ramirez-Zamora, B. Shickel (Gainesvile, USA)

    Objective: To enhance clinical decision-making in PD management by developing and validating a conformal prediction framework that forecasts Levodopa Equivalent Daily Dose (LEDD) changes with…
  • 2025 International Congress

    Modeling Levodopa Resistance in Parkinson’s Disease: A Novel Approach Targeting Locus Coeruleus Degeneration

    A. Goel, R. Goel (Bathinda, India)

    Objective: To develop a Parkinson’s disease (PD) model replicating levodopa (LD) resistance by incorporating degeneration of both the substantia nigra (SN) and locus coeruleus (LC),…
  • 2025 International Congress

    Down-titration of levodopa complicated by catatonia

    D. Newbold, . (New York, USA)

    Objective: Provide evidence that reductions in levodopa can trigger catatonia Background: Dopamine dysregulation syndrome (DDS) occurs when patients crave and self-up-titrate levodopa, often leading to…
  • 2025 International Congress

    Levodopa and DBS Produce Discordant Effects on Parkinsonian Features

    T. Lee, D. Ramesh, J. Perlmutter, J. Younce (Chapel Hill, USA)

    Objective: To compare the effect of levodopa vs deep brain stimulation on specific motor features of advanced Parkinson disease. Background: Levodopa (LD) is the gold…
  • 2025 International Congress

    Electrochemical Sensing for Accurate L-Dopa Detection in Parkinson’s disease

    P. Dutta, A. Eshore, P. Guha, M. Acharya (Kharagpur, India)

    Objective: This study aims to develop a cost-effective, portable electrochemical sensor for real-time L-dopa monitoring in PD patients, addressing the limitations of current detection techniques.…
  • 2025 International Congress

    Sustained Motor Symptom Efficacy With Long-Term Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) Treatment – Data From The ELEGANCE Interim Analysis

    B. Amlani, N. Smith (Reading, United Kingdom)

    Objective: To evaluate the long-term effect on motor symptoms of advanced Parkinson’s disease (PD) following up to two years of treatment with LECIG by analysis…
  • 2025 International Congress

    Medication therapy in Parkinson’s disease patients: a cross-sectional study at the University Medical Center at Ho Chi Minh City, Vietnam

    T. Dang, T. Tran (HO CHI MINH, Viet Nam)

    Objective: To determine the rate of drugs prescribed to treat Parkinson's disease motor symptoms, the rate of the types of drug combinations, and the frequency…
  • 2025 International Congress

    Impact of IPX203 (ER CD-LD) on nighttime sleep in patients with Parkinson’s disease experiencing motor fluctuations: A post hoc analysis of the RISE-PD trial

    R. Hauser, A. Espay, O. Vaou, J. Aldred, S. Allard, G. Banisadr, S. Fisher (Tampa, USA)

    Objective: To explore the effects of IPX203 on nighttime sleep and motor states in patients with Parkinson’s disease (PD) experiencing motor fluctuations. Background: Sleep disturbances…
  • 2025 International Congress

    Levodopa Effects In Swedd: Clinical And Kinematic Insights From A Case Report

    D. Birreci, L. Angelini, A. Martini, S. Grandolfo, M. de Riggi, S. Aloisio, M. Bologna (Rome, Italy)

    Objective: To investigate the clinical and neurophysiological effects of levodopa treatment in a patient diagnosed with SWEDD. Background: A subset of patients with clinical features…
  • 2025 International Congress

    Treatment Of Advanced Parkinson’s With Levodopa–Entacapone–Carbidopa Intestinal Gel – Impact On Dyskinesia

    B. Amlani, N. Smith (Reading, United Kingdom)

    Objective: To evaluate the effect of long-term treatment with levodopa–entacapone–carbidopa intestinal gel (LECIG) infusion on daily time with dyskinesia in people with advanced Parkinson’s disease…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 62
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley